Drugs

Clarity Sought on FDA New Approach Methodologies Guide

David McFarland

— 1 min read
Share

The Biotechnology Innovation Organization (BIO) says an FDA draft guidance on general considerations for using new approach methodologies (NAMs) in drug development “marks an important step toward establishing a flexible science-based framework for integrating NAMs into drug development.” The BIO comment letter highlights areas where the association believes additional clarity could further support the guidance’s objectives while maintaining regulatory flexibility.

“Overall,” the letter concludes, “BIO supports FDA’s flexible and science-driven approach to NAM integration and appreciates the agency’s commitment to advancing alternative methods in drug development. Maintaining this flexibility will be important as the field continues to evolve. At the same time, additional clarity and illustrative examples would provide sponsors with greater confidence in how NAMs will be evaluated and applied in regulatory decision-making.” The association also provides specific, line-by-line comments.

In its letter, Pharmaceutical Research and Manufacturers of America calls on FDA to revise its draft guidance to:

  • clarify expectations for the use of NAMs within the weight of evidence, including when NAMs may be deemed fit-for-purpose to serve as supportive partial replacement or standalone evidence, and provide decision trees to clarify the distinction between validation and fit-for-purpose relative to the weight of evidence and degree of risk;
  • provide additional examples, decision frameworks, and appendices illustrating acceptable NAM applications across various domains and modalities;
  • enhance transparency and predictability through further development of a centralized database of validated NAMs accepted by FDA;
  • clarify operational considerations, including submission format and placement, meeting pathways, and expectations for early engagement;
  • address variability across modalities and FDA Centers, and promote consistency across review divisions; and
  • advance international harmonization and acceptance of NAMs, validation standards, and evidentiary expectations.

The Critical Path Institute says the draft guidance “represents a significant and timely advancement in regulatory science and reflects FDA’s continued leadership in modernizing evidentiary frameworks to support innovation in drug development.” It provides both general and specific comments.

Finally, the Physicians Committee for Responsible Medicine says it welcomes the draft guidance as it furthers FDA’s priority to move away from reliance on animal testing toward human-centric methods, thereby supporting the mission to advance public health by helping make medical products safer, more effective, and more affordable. It submits specific comments and suggested revisions to the guidance.

Read more